Source:https://newsroom.wiley.com/press-release/psycho-oncology/researchers-examine-health-behaviors-after-childhood-cancer-diagnosis Reviewed by James Ives, M.Psych. (Editor)Nov 7 2018In a Psycho-Oncology study of childhood cancer survivors, several health behaviors fell short of expectations for exercise and diet during early survivorship, and they remained sub-optimal upon reaching five years post-diagnosis.The study followed families of children with cancer (ages 5-17 at recruitment) from diagnosis through five years. Three years and five years post-diagnosis, 82 survivors and 103 mothers of survivors completed questionnaires assessing exercise, dietary, and sleep patterns among survivors.Related StoriesUsing machine learning algorithm to accurately diagnose breast cancerBacteria in the birth canal linked to lower risk of ovarian cancerHow cell-free DNA can be targeted to prevent spread of tumorsAt three- and five-years post-diagnosis, mothers’ and survivors’ responses indicated that few survivors engaged in appropriate levels of low-intensity exercise, fruit/vegetable intake, and dairy consumption; however, most survivors engaged in recommended levels of high intensity exercise, fast food restriction, and sleep. Higher income was associated with decreased intake of fast food over time, whereas lower income was associated with increased intake.”Childhood cancer survivors are at elevated risk for a multitude of conditions later in life, and greater engagement in healthy habits may be particularly important for this population,” said lead author Rachel Fisher, of Nationwide Children’s Hospital, in Columbus. “These findings emphasize that there is much work to be done to ensure that these survivors enjoy full, healthy lives.”
Reviewed by James Ives, M.Psych. (Editor)Dec 6 2018Children’s Hospital of Philadelphia (CHOP) celebrates a pivotal moment in medicine: approval by the European Commission (EC) of LUXTURNA® (voretigene neparvovec), the first and only gene therapy for patients with an inherited retinal disease, last month. This also makes LUXTURNA the first gene therapy for a genetic disease that has received regulatory approval in both the U.S. and European Union (EU).The EC approved LUXTURNA, a one-time gene therapy for the treatment of vision loss due to inherited retinal dystrophy caused by confirmed biallelic RPE65 mutations, in pediatric and adult patients who have sufficient viable retinal cells. RPE65 -mediated inherited retinal disease is a progressive condition that leads to total blindness in most patients.The authorization is valid in all 28 member states of the EU, as well as Iceland, Liechtenstein and Norway. In December 2017, the U.S. Food and Drug Administration (FDA) approved LUXTURNA for use in patients in the U.S.”The European Commission’s approval of LUXTURNA highlights the vital role of pediatric research in developing breakthrough cures,” said Bryan Wolf, MD, PhD, Chief Scientific Officer and Chair of the Department of Biomedical and Health Informatics at Children’s Hospital of Philadelphia. “The research conducted as a collaborative effort between CHOP’s Raymond G. Perelman Center for Cellular and Molecular Therapeutics (CCMT) and investigators at the Perelman School of Medicine at the University of Pennsylvania laid the groundwork for this revolutionary gene therapy, which was developed and is now manufactured by Spark Therapeutics. Today, we are thrilled to see LUXTURNA approved as a therapy for children and adults outside the U.S.”Related StoriesGuidelines to help children develop healthy habits early in lifeResearchers identify gene mutations linked to leukemia in children with Down’s syndromeRevolutionary gene replacement surgery restores vision in patients with retinal degenerationCHOP founded Spark Therapeutics in 2013 in an effort to accelerate the timeline for bringing new gene therapies to market. Spark’s mission, to create a world where no life is limited by genetic disease, was to build on the foundational research conducted over a multi-year period by the CHOP and Penn Medicine teams.Beginning in 2000, the initial research for LUXTURNA was conducted by Jean Bennett, MD, PhD, F.M. Kirby professor of Ophthalmology at the Perelman School of Medicine at the University of Pennsylvania’s Scheie Eye Institute, and Albert M. Maguire, MD, a professor of Ophthalmology at Penn’s Perelman School of Medicine and an attending physician at CHOP. Bennett and Maguire joined forces with then-CHOP researcher Katherine A. High, MD, a gene therapy pioneer who directed the CCMT and who is now Spark’s President and head of research and development. Dr. Maguire served as a Principal Investigator of the therapy’s clinical trials.In the U.S., the gene therapy is currently administered at 10 treatment centers by leading retinal surgeons who receive training provided by Spark Therapeutics on the administration procedure.In January 2018, Spark Therapeutics entered into a licensing and supply agreement with Novartis covering development, registration and commercialization rights to LUXTURNA in markets outside the U.S. Upon the transfer of the marketing authorization from Spark Therapeutics to Novartis. Novartis can commercialize LUXTURNA in the EU/EEA. Novartis already has exclusive rights to pursue development, registration and commercialization in all other countries outside the U.S., and Spark Therapeutics will supply the gene therapy to Novartis.Source: https://www.chop.edu/news/children-s-hospital-celebrates-european-commission-approval-first-its-kind-gene-therapy
Revellers sprint near bulls and steers during the running of the bulls at the San Fermin festival in Pamplona, Spain, July 12, 2019. REUTERS/Susana VeraPAMPLONA, Spain (Reuters) – One man was gored and at least four other people were sent to hospital with injuries following the sixth day of the running of the bulls at the San Fermin festival in the northern Spanish city of Pamplona, the Red Cross said on Friday. Each morning at 8 a.m. (0600 GMT) between July 7 and 14 as part of the week-long festival thousands line the streets of the medieval city to take part in the centuries-old tradition of running with the bulls. In the 875-meter chase through the narrow streets of the city a half dozen, specially bred, aggressive bulls, led by six larger, more docile steers race from their pen to the city’s bull ring as runners dodge horns and stampeding hooves. Friday’s run lasted just two minutes and 18 seconds, though most runners sprint just briefly before being overtaken by the herd. The bulls are later killed in the bull ring by matadors. Reporting by Susana Vera; writing by Paul Day; editing by Jason NeelyOur Standards:The Thomson Reuters Trust Principles.
Defence Minister Nirmala Sitharaman – THE HINDU COMMENTS Defence Minister Nirmala Sitharaman on Tuesday sought to turn the tables around, blaming the previous Congress-led UPA regime for keeping State-run Hindustan Aeronautics Ltd (HAL) out of the Rafale fighter jet deal.The Congress has been accusing the Narendra Modi government of ignoring the public sector unit in the manufacture of the combat aircraft, and favouring the Anil Ambani’s Reliance Defence.Sitharaman claimed the price negotiated for the Rafale by the Modi government was nine per cent cheaper than the UPA deal.“One of the things that did not happen during the UPA was that between Dassault Aviation and HAL they could not agree on production terms. That is why they could not go together. So that speaks for which government failed in terms of getting them together,” said Sitharaman, speaking at an interaction organised by the Indian Women’s Press Corps on Tuesday.Sitharaman was responding to questions based on Congress leader and former defence minister AK Antony’s allegations that if the UPA deal wasn’t cancelled by this government, HAL would’ve acquired the state-of-the-art technology through the transfer of technology and would’ve gained experience to manufacture fighter aircraft.“The previous government could have done anything to strengthen HAL’s offer to ensure that HAL’s terms were appealing enough for Dassault to conclude the deal with it. So the entire issue of HAL not being chosen happened during there time. “You (UPA) have not taken care of HAL. You have not made the terms appealing enough for HAL to bid successfully with Dassault. You have not finalised buying of Rafale aircraft for depleting squadron of IAF,” she said, stressing that questions should be posed to the Congress on HAL.The Congress has accused the Modi government of causing a loss of ₹41,000 crore to the public exchequer by purchasing Rafale aircraft from the French government with the same configuration at thrice the price.Responding to allegations on the pricing front, the Minister said, “We have responded saying your basic price and the basic price that I am getting at, when compared with all the escalation and other things, is 9 per cent cheaper.” Defence Minister claims Modi govt’s procuring the jets 9% cheaper Published on ministers (government) September 18, 2018 COMMENT SHARE SHARE EMAIL SHARE defence